Anebulo Pharmaceuticals Initiates Phase 1 Trial for IV Cannabis Toxicity Antidote, Bolstered by NIDA Funding
AUSTIN, Texas – Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage biopharmaceutical company, has announced a significant milestone in its drug development program, dosing the first subjects in a Phase 1 single ascending dose (SAD) study of its investigational intravenous (IV) treatment, selonabant. This crucial trial, conducted in healthy young adults, is supported by a collaborative…

